A pending announcement from the Trump administration linking pain relief drug acetaminophen with autism has stirred investor anxiety in the drug’s primary producer. The share price of Kenvue, the parent company of Tylenol, is down more than 5% on Monday following President Donald Trump’s comments that acetaminophen is “a very big factor” for the risk of autism. Kenvue’s stock is down 25% over the last six months as the company has worked—against investor sentiment—to navigate repeated claims about the pain reliever’s alleged link with autism.
On Sunday during the memorial for slain conservative activist Charlie Kirk, Trump indicated the White House would release information about the cause of autism, including its claimed connection to taking the pain reliever during pregnancy.
